Search

Your search keyword '"Jiang, Hanfang"' showing total 157 results
Start Over Author "Jiang, Hanfang"
157 results on '"Jiang, Hanfang"'

5. Ammonium sulfate denatures transport medium less dependent on guanidinium isothiocyanate and enables SARS-CoV-2 RNA and antigen detection compatibility

Author

Liu, Ge, primary, Xu, Jiapeng, additional, Huang, Yuanyuan, additional, Ye, Wei, additional, Li, Jieyu, additional, Yan, Ran, additional, Luo, Qiting, additional, Zhou, Xinrui, additional, Cai, Yingna, additional, Jiang, Hanfang, additional, Lu, Xiujing, additional, Zheng, Kai, additional, He, Zhendan, additional, and Zhu, Qinchang, additional

Published
2024
Full Text
View/download PDF

6. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China

Author

Jiang, Hanfang, primary, Zhong, Jianxin, additional, Wang, Jing, additional, Song, Guohong, additional, Di, Lijun, additional, Shao, Bin, additional, Zhang, Ruyan, additional, Liu, Yaxin, additional, Zhu, Anjie, additional, Wang, Nan, additional, and Li, Huiping, additional

Published
2024
Full Text
View/download PDF

10. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer.

Author

Liu, Xiaoran, Ran, Ran, Shao, Bin, Rugo, Hope S, Yang, Yanlian, Hu, Zhiyuan, Wei, Zewen, Wan, Fengling, Kong, Weiyao, Song, Guohong, Jiang, Hanfang, Liang, Xu, Zhang, Ruyan, Yan, Ying, Xu, Guobing, and Li, Huiping

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Clinical Research, Breast Cancer, Breast cancer, nanotechnology, circulating tumor cell, immunology, Oncology & Carcinogenesis
Abstract

ObjectiveTriple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC.MethodsIn present prospective cohort study, we used the Pep@MNPs method to enumerate CTCs in baseline blood samples from 75 patients with TNBC (taken at inclusion in this study) and analyzed correlations between CTC numbers and outcomes and other clinical parameters.ResultsMedian PFS was 6.0 (range: 1.0-25.0) months for the entire cohort, in whom we found no correlations between baseline CTC status and initial tumor stage (P=0.167), tumor grade (P=0.783) or histological type (P=0.084). However, among those getting first-line treatment, baseline CTC status was positively correlated with ratio of peripheral natural killer (NK) cells (P=0.032), presence of lung metastasis (P=0.034) and number of visceral metastatic site (P=0.037). Baseline CTC status was predictive for PFS in first-line TNBC (P=0.033), but not for the cohort as a whole (P=0.118). This prognostic limitation of CTC could be ameliorated by combining CTC and NK cell enumeration (P=0.049).ConclusionsBaseline CTC status was predictive of lung metastasis, peripheral NK cell ratio and PFS in TNBC patients undergoing first-line treatment. We have developed a combined CTC-NK enumeration strategy that allows us to predict PFS in TNBC without any preconditions.

Published
2018

13. Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options

Author

Jiang, Hanfang and Rugo, Hope S

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Breast Cancer, Clinical Trials and Supportive Activities, Biotechnology, 6.1 Pharmaceuticals, 5.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, breast cancer, HER2, lapatinib, pertuzumab, ado-trastuzumab emtansine, Oncology and carcinogenesis
Abstract

Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) remains an incurable disease, and approximately 25% of patients with HER2+ early breast cancer still relapse after adjuvant trastuzumab-based treatment. HER2 is a validated therapeutic target that remains relevant throughout the disease process. Recently, a number of novel HER2 targeted agents have become available, including lapatinib (a small molecule tyrosine kinase inhibitor of both HER2 and the epidermal growth factor receptor), pertuzumab (a new anti-HER2 monoclonal antibody) and ado-trastuzumab emtansine (T-DM1, a novel antibody-drug conjugate), which provide additional treatment options for patients with HER2+ MBC. The latest clinical trials have demonstrated improved outcome with treatment including pertuzumab or T-DM1 compared with standard HER2 targeted therapy. Here we review the clinical development of approved and investigational targeted agents for the treatment of HER2+ MBC, summarize the latest results of important clinical trials supporting use of these agents in the treatment of HER2+ MBC, and discuss how these results impact therapeutic options in clinical practice.

Published
2015

15. Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study.

Author

Liu, Yaxin, Song, Guohong, Di, Lijun, Jiang, Hanfang, Ran, Ran, Zhang, Ruyan, Zhang, Yan, and Li, Huiping

Subjects
BREAST cancer prognosis, DISEASE progression, METASTASIS, TREATMENT effectiveness, RANDOMIZED controlled trials, PRE-tests & post-tests, COMPARATIVE studies, CANCER patients, TREATMENT delay (Medicine), DESCRIPTIVE statistics, PACLITAXEL, STATISTICAL sampling, PROGRESSION-free survival, TERMINATION of treatment, BREAST tumors, PATIENT safety, EVALUATION
Abstract

Background: This head-to-head study compared a 3-week versus 4-week schedule of nab-paclitaxel in patients with metastatic breast cancer (mBC). Methods: Patients with HER2-negative mBC were enrolled and randomly assigned (1:1) to receive nab-paclitaxel for a 3-week schedule (125 mg/m2 on days 1 and 8) or a 4-week schedule (same dose on days 1, 8, and 15) until disease progression or treatment intolerance. Patients with intolerable toxicities were allowed to receive a maintenance regimen after benefiting from nab-paclitaxel. The primary endpoint was progression-free survival (PFS). Results: Ninety-four patients were included in the analysis (n = 47 in each arm). A longer median PFS (mPFS) was observed in the 3-week versus the 4-week schedule in the overall population (not reached vs. 6.8 months; hazard ratio [HR] = 0.44; P = .029). Patients in the 2 arms had a similar overall survival (28.0 vs. 25.8 months), objective response rate (51.1% vs. 48.9%), and disease control rate (93.6% vs. 80.9%). The 3-week schedule was associated with a lower rate of toxicity-related treatment discontinuation (8.5% vs. 29.8%) and dose delays (6.4% vs. 23.4%). Conclusion: This study demonstrated the better antitumor activity and safety profile of a 3-week over 4-week nab-paclitaxel schedule in HER2-negative mBC, suggesting that a 3-week schedule may be a better treatment regimen in clinical practice (ClinicalTrials.gov Identifier: NCT04192331). This study compared a 3-week versus 4-week schedule of nab -paclitaxel in patients with metastatic breast cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

Author

Liang, Xu, primary, Xue, Junli, additional, Ge, Xiaoxiao, additional, Li, Jin, additional, Li, Huiping, additional, Xue, Liqiong, additional, Di, Lijun, additional, Tang, Wenbo, additional, Song, Guohong, additional, Li, Qun, additional, Jiang, Hanfang, additional, Zhao, Wei, additional, Lin, Fengjuan, additional, Shao, Bin, additional, Yang, Xiugao, additional, Wu, Zhufeng, additional, Zhang, Tianyi, additional, Wang, Chenchen, additional, and Guo, Ye, additional

Published
2022
Full Text
View/download PDF

24. Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study.

Author

Jiang, Hanfang, Li, Huiping, Song, Guohong, Di, Lijun, Shao, Bin, Yan, Ying, Liu, Xiaoran, Chen, Yifei, Zhang, Ruyan, Ran, Ran, Liu, Yaxin, Gui, Xinyu, Wang, Nan, and Wang, Huan

Abstract

Purpose: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) heavily pretreated with anthracycline and taxanes. Methods: In this single-arm, phase II study, patients with HER2-negative MBC previously treated with anthracycline and taxanes as second- to fifth chemotherapy received PLD (Duomeisu®, generic doxorubicin hydrochloride liposome) 40 mg/m2 every 4 weeks until disease progression, unacceptable toxicity, or completion of six cycles. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), and safety. Results: Of 44 enrolled patients (median age, 53.5 years; range, 34–69), 41 and 36 were evaluable for safety and efficacy, respectively. In total, 59.1% (26/44) of patients had ≥ 3 metastatic sites, 86.4% (38/44) had visceral disease, and 63.6% (28/44) had liver metastases. Median PFS was 3.7 months (95% confidence interval [CI] 3.3–4.1) and median OS was 15.0 months (95% CI 12.1–17.9). ORR, DCR, and CBR were 16.7%, 63.9%, and 36.1%, respectively. The most common adverse events (AEs) were leukopenia (53.7%), fatigue (46.3%), and neutropenia (41.5%), with no grade 4/5 AEs. The most common grade 3 AEs were neutropenia (7.3%) and fatigue (4.9%). Patients experienced palmar-plantar-erythrodysesthesia (24.4%, 2.4% grade 3), stomatitis (19.5%, 7.3% grade 2), and alopecia (7.3%). One patient displayed a left ventricular ejection fraction decline of 11.4% from baseline after five cycles of PLD therapy. Conclusion: PLD (Duomeisu®) 40 mg/m2 every 4 weeks was effective and well-tolerated in patients with HER2-negative MBC heavily pretreated with anthracycline and taxanes, revealing a potentially viable treatment option for this population. Trial registration Chinese Clinical Trial Registry: ChiCTR1900022568. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Additional file 4 of Comparison and development of a metagenomic next-generation sequencing protocol for combined detection of DNA and RNA pathogens in cerebrospinal fluid

Author

Jiang, Hanfang, Xing, Zhihao, Liu, Xiaorong, Chai, Qiang, Xin, Zefeng, Zhu, Chunqing, Lin, Ruihong, Deng, Xuwen, Cui, Dong, Gao, HongDan, and Ma, Dongli

Abstract

Additional file 4: Fig. S1. The microbial reads percentage of EBV samples and EV71 samples. A. The microbial reads percentage of EBV samples in methods Total DNA , Total NA ,Total RNA and WTA. B. The microbial reads percentage of EV71 samples in methods Total NA ,Total RNA and WTA. Fig. S2. NR, RPMratio and Coverage percent of target pathogens. Subfigure A/B/C shows NR/ RPMratio/coverage percentage of E. coli respectively comparing four sample pretreatment/nuclear acid extraction methods including Microbial DNA, Total DNA, Total NA and Total RNA. The red dots represent concentration of 106cfu/ml and the blue dots represent concentration of 5x104 cfu/ml. Subfigure D/E/F shows NR/ RPMratio/coverage percentage of SP comparing four sample pretreatment/nuclear acid extraction methods respectively. The red dots represent concentration of 106cfu/ml and the blue dots represent concentration of 5x104 cfu/ml. Subfigure G/H/I shows NR/RPMratio/coverage percentage of EBV respectively comparing four sample pretreatment/nuclear acid extraction methods including Total DNA, Total NA, Total RNA and WTA. The red dots represent concentration of 5x105 copies/ml and the blue dots represent concentration of 5x103 copies/ml. Subfigure J/K/L shows NR/RPMratio/coverage percentage of EV71 respectively comparing four sample pretreatment/nuclear acid extraction methods respectively. The red dots represent concentration of 5x105 copies/ml and the blue dots represent concentration of 5x103 copies/ml. Fig. S3. Genomic coverage of pathogens in CSF from encephalitis patients. A. Genomic coverage of Echovirus 30 in clinical CSF 0006. B. Genomic coverage of coxsackievirus B5 in clinical CSF 0010. Fig. S4. Genomic coverage of Streptococcus pneumoniae, Streptococcus thermophilus and Mogibacterium diversum in sample Microbial DNA-ILL -1. A. Genomic coverage of Streptococcus pneumoniae. B. Genomic coverage of Streptococcus thermophilus. C. Genomic coverage of Mogibacterium diversum.

Published
2022
Full Text
View/download PDF

29. Contributions of ARID5B, IKZF1, PIP4K2A, and GATA3Gene Polymorphisms to Childhood Acute Lymphoblastic Leukemia in a Chinese Population

Author

Liu, Xiaorong, Xiao, Min, Xing, Zhihao, Jiang, Hanfang, Zhu, Chunqing, Zhang, Xingliang, Li, Weiqiong, Wang, Zijie, Wu, Feng, and Chen, Yunsheng

Abstract

Various studies have shown that single nucleotide polymorphisms in the AT-rich interaction domain 5B (ARID5B), IKAROS family zinc finger 1 (IKZF1), phosphatidylinositol-5-phosphate 4-kinase type 2 alpha (PIP4K2A), and GATA binding protein 3 (GATA3) genes may be associated with the susceptibility and prognosis of childhood acute lymphoblastic leukemia (ALL). The present study aimed to investigate the association of ARID5B rs10821936, IKZF1 rs4132601, PIP4K2A rs7088318, and GATA3 rs3824662gene polymorphisms with the susceptibility and prognosis of childhood ALL in China. We found that the C allele of rs10821936 (ARID5B) and the A allele of rs3824662 (GATA3) were associated with an increased risk of childhood ALL in the Chinese population. There was no significant difference in frequencies of rs4132601 (IKZF1) and rs7088318 (PIP4K2A) genotypes and alleles between the childhood ALL and control groups. We observed that CC genotype of rs10821936 (ARID5B) was associated with increased rates of high-risk and moderate-risk childhood ALL. The rs10821936 (ARID5B) could serve as a potential biomarker for assessing the risk of childhood ALL in Chinese children.

Published
2023
Full Text
View/download PDF

30. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences

Author

Ren, Jun, Di, Lijun, Song, Guohong, Yu, Jing, Jia, Jun, Zhu, Yuling, Yan, Ying, Jiang, Hanfang, Liang, Xu, Che, Li, Zhang, Jie, Wan, Fengling, Wang, Xiaoli, Zhou, Xinna, and Lyerly, Herbert Kim

Published
2013
Full Text
View/download PDF

32. Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)

Author

Jiang, Hanfang, primary, Zhang, Ruyan, additional, Liu, Xiaoran, additional, Ran, Ran, additional, Zhang, Jiayang, additional, Liu, Yaxin, additional, Gui, Xinyu, additional, Chen, Yifei, additional, Li, Kun, additional, Shao, Bin, additional, Yan, Ying, additional, Liang, Xu, additional, Song, Guohong, additional, Di, Lijun, additional, and Li, Huiping, additional

Published
2021
Full Text
View/download PDF

35. A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer.

Author

Li, Huiping, primary, Jiang, Hanfang, additional, Yin, Yongmei, additional, Tong, Zhongsheng, additional, Ouyang, Quchang, additional, Shen, Kunwei, additional, Yuan, Zhongyu, additional, Geng, Cuizhi, additional, Ran, Ran, additional, Zhang, Ruyan, additional, Liu, Ya-Xin, additional, Zhang, Jiayang, additional, Li, Wei, additional, Qu, Qing, additional, Zhou, Qiaoxia, additional, Dong, Xunwei, additional, Meng, Luping, additional, Zhu, Xiaoyan, additional, Yi, Zhen, additional, and Tong, Youzhi, additional

Published
2021
Full Text
View/download PDF

40. Abstract P1-19-40: Apatinib in the treatment of HER-2 negative advanced breast cancer with chest wall metastasis multicenter phase II clinical study

Author

Li, Huiping, primary, Geng, Cuizhi, additional, Song, Guohong, additional, Jiang, Hanfang, additional, Tong, Zhongshen, additional, Yang, Junlan, additional, Ran, Ran, additional, Zhang, Ruyan, additional, Liu, Yaxin, additional, Gui, Xinyu, additional, Wei, Maorong, additional, and Xue, Lu, additional

Published
2020
Full Text
View/download PDF

41. Abstract P2-17-05: Evaluation of safety, pharmacokinetics and pharmacodynamics of proxalutamide (GT0918), a potent androgen receptor (AR) blocker, in patients with metastatic breast cancer (mBC): Phase I dose escalation trial

Author

Li, Huiping, primary, Ran, Ran, additional, Song, Guohong, additional, Jiang, Hanfang, additional, Zhang, Ruyan, additional, Liu, Yaxin, additional, Meng, Luping, additional, Zhang, Phoebe, additional, Chen, Ke, additional, Zhou, Qiaoxia, additional, Zhou, Karl, additional, and Tong, Youzhi, additional

Published
2020
Full Text
View/download PDF

44. Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall

Author

Gui, Xinyu, Li, Huiping, Song, Guohong, Shao, Bin, and Jiang, Hanfang

Subjects
Vascular Endothelial Growth Factor A, Angiogenesis Inhibitors, Antineoplastic Agents, Triple Negative Breast Neoplasms, bevacizumab, Middle Aged, Thoracic Neoplasms, triple negative, Carcinoma, Ductal, breast cancer, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Clinical Case Report, Cisplatin, Thoracic Wall, Research Article, chest wall metastasis
Abstract

Rationale: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC. Patient concerns: We reported a 49-year-old woman presenting with a giant breast tumor. Diagnoses: Stage IV TNBC with chest wall metastasis. Interventions: The patient underwent long-term use of bevacizumab combined with chemotherapy. Outcomes: The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed. Lessons: Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.

Published
2018

46. Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10‐year (2006–2015) retrospective hospitalization summary report‐based study

Author

Bao, Xiaoyuan, primary, Sun, Kexin, additional, Tian, Xin, additional, Yin, Qiongzhou, additional, Jin, Meng, additional, Yu, Na, additional, Jiang, Hanfang, additional, Zhang, Jun, additional, and Hu, Yonghua, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results